Development and validation of an Opioid Attractiveness Scale: A novel measure of the attractiveness of opioid products to potential abusers

Harm Reduction Journal

Volumn 3, Issue , 2006, Pages

  Butler, Stephen F ^a   Benoit, Christine ^a   Budman, Simon H ^a,b   Fernandez, Kathrine C ^a   McCormick, Cynthia ^c   Venuti, Synne Wing ^a   Katz, Nathaniel ^a,d  

^a INFLEXXION INC   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c McCormick Consultation   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; BUTORPHANOL TARTRATE; FENTANYL; FENTANYL CITRATE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROMORPHONE; METHADONE; MORPHINE SULFATE; NOSE SPRAY; OPIATE; OXYCODONE; PENTAZOCINE; PERCOCET; STADOL NASAL SPRAY; TALWIN NX;

ARTICLE; CORRELATION ANALYSIS; DRUG FORMULATION; HUMAN; INTERNAL CONSISTENCY; MEDICAL LIABILITY; OPIATE ADDICTION; PRESCRIPTION; PSYCHOMETRY; RATING SCALE; RELIABILITY; SCORING SYSTEM; SUBSTANCE ABUSE; VALIDATION PROCESS;

EID: 33644505488     PISSN: 14777517     EISSN: None     Source Type: Journal    
DOI: 10.1186/1477-7517-3-5     Document Type: Article

References (23)

1. O'Donnell JA: Social factors and follow-up studies in opioid addiction. Res Publ Assoc Res Nerv Ment Dis 1968, 46:333-346.
2. Weissman S: The significance of diagnosis in the treatment of narcotics addicts. Int J Addict 1970, 5:717-730.
3. Whitman BY, Croughan JL, Miller JP, McKay J: Nonpsychiatric predictors of narcotic dependence: a prospective study with a 5-year follow-up. Int J Addict 1982, 17:473-491.
4. Luthar SS, Anton SF, Merikangas KR, Rounsaville BJ: Vulnerability to drug abuse among opioid addicts' siblings: individual, familial, and peer influences. Compr Psychiatry 1992, 33:190-196.
5. Health NI: Prescription opioid abuse and use in the treatment of pain. NIH request for application announcement. http://grants nih/gov/grants/ guide/rfa-files/RFA-DA-06-005 html 2005, 23 November:.
6. Zacny J, Bigelow G, Compton P, Foley K, Iguchi M, Sannerud C: College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend 2003, 69:215-232.
7. Vocci FJ, Acri J, Elkashef A: Medication development for addictive disorders: the state of the science. Am J Psychiatry 2005, 162:1432-1440.
8. Centers for Disease Control and Prevention (CDC): Unintentional opiate overdose deaths - King County, Washington, 1990-1999. MMWR Morb Mortal Wkly Rep 2000, 49:636-640 [http://PM:10926306].
9. Centers for Disease Control and Prevention (CDC): Unintentional deaths from drug poisoning by urbanization of area - New Mexico 1994-2003. MMWR Morb Mortal Wkly Rep 2005, 54:870-873.
10. CALLAWAY E: The misuse of narcotics by patients suffering from cancer. CA Cancer J Clin 1960, 10:33-36.
11. Lipinski E: Motivation in drug misuse. Some comments on agent, environment, host. JAMA 1972, 219:171-175.
12. Cohen J, Schamroth A. The challenge of illicit drug addiction for general practice. Drug Alcohol Depend 1990, 25:315-318.
13. Woolf CJ, Hashmi M: Use and abuse of opioid analgesics: potential methods to prevent and deter non-medical consumption of prescription opioids. Curr Opin Investig Drugs 2004, 5:61-66.
14. Adams MP, Ahdieh H: Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. Drugs R D 2005, 6:91-99.
15. Gammaitoni AR, Galer BS, Lacouture P, Domingos J, Schlagheck T: Effectiveness and safety of new oxycodone/acetaminophen formulations with reduced acetaminophen for the treatment of low back pain. Pain Med 2003, 4:21-30.
16. Drover DR, Angst MS, Valle M, Ramaswamy B, Naidu S, Stanski DR, Verotta D: Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology 2002, 97:827-836.
17. Portenoy RK, Sciberras A, Eliot L, Loewen G, Butler J, Devane J: Steady-state pharmacokinetic comparison of a new, extended-release, once-daily morphine formulation, Avinza, and a twice-daily controlled-release morphine formulation in patients with chronic moderate-to-severe pain. J Pain Symptom Manage 2002, 23:292-300.
18. Cronbach LJ: Coefficient alpha and the internal structure of tests. Psychometrika 1951, 16:297-334.
19. Siegel S: Nonparametric statistics for the behavioral sciences. New York McGraw Hill 1956.
20. Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174.
21. Gilson AM, Ryan KM, Joranson DE, Dahl JL: A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. J Pain Symptom Manage 2004, 28:176-188.
22. Helman CG: 'Tonic', 'fuel' and 'food': social and symbolic aspects of the long-term use of psychotropic drugs. Soc Sci Med [B] 1981, 15:521-533.
23. Cook TD, Campbell DT: Quasi-experimentation: design and analysis issues for field settings. Chicago, IL: Rand McNally College Publishing Co 1979.